Financial Markets Research: Palatin Technologies' Bremelanotide

Summary

Introduction

Palatin Technologies' bremelanotide (PT-141) is a novel melanocortin receptor agonist that is believed to be the only agent currently in development for the treatment of both erectile dysfunction (ED) and female sexual dysfunction (FSD).

Highlights

While there would appear to be much potential for an agent that can improve libido in both male and female patients without acting directly on the vascular system, we believe that unclear efficacy of PTN's bremelanotide and substantial regulatory risk diminish the potential this agent in the treatment of male and female sexual dysfunction.Pending results from the two Phase IIb trials which are expected later this year, we forecast US bremelanotide revenues well below the blockbuster potential estimated by some Wall Street analysts.

Scope

• Explores the regulatory and commercial potential for PTN's bremelanotide, a novel agent in development for male and female sexual dysfunction
• Interviews with 7 urologists familiar with bremelanotide and its clinical data and potential for the treatment of male and female sexual dysfunction

Reasons to Purchase

• Understand the commercial potential for Palatin Technologies' Bremelanotide through in-depth analysis based on interviews with leading experts
• Anticipate likely changes in the future market dynamics for erectile dysfunction therapies if approval of bremelanotide occurs

Content